More than 80 clinical trials launch to test coronavirus treatments

Maxmen, Amy

doi:10.1038/d41586-020-00444-3

Cited by 126 publications

(103 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We hope our prediction results may support experimental therapeutic options for China and other countries suffering from the SARS-CoV-2 pandemic and align with recent clinical trials (35).…”

Section: Discussionsupporting

confidence: 71%

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Beck

Shin

Choi

et al. 2020

Computational and Structural Biotechnology Journal

653

496

View full text Add to dashboard Cite

The infection of a novel coronavirus found in Wuhan of China (SARS-CoV-2) is rapidly spreading, and the incidence rate is increasing worldwide. Due to the lack of effective treatment options for SARS-CoV-2, various strategies are being tested in China, including drug repurposing. In this study, we used our pre-trained deep learning-based drug-target interaction model called Molecule Transformer-Drug Target Interaction (MT-DTI) to identify commercially available drugs that could act on viral proteins of SARS-CoV-2. The result showed that atazanavir, an antiretroviral medication used to treat and prevent the human immunodeficiency virus (HIV), is the best chemical compound, showing an inhibitory potency with Kd of 94.94 nM against the SARS-CoV-2 3C-like proteinase, followed by remdesivir (113.13 nM), efavirenz (199.17 nM), ritonavir (204.05 nM), and dolutegravir (336.91 nM). Interestingly, lopinavir, ritonavir, and darunavir are all designed to target viral proteinases. However, in our prediction, they may also bind to the replication complex components of SARS-CoV-2 with an inhibitory potency with Kd < 1,000 nM. In addition, we also found that several antiviral agents, such as Kaletra (lopinavir/ritonavir), could be used for the treatment of SARS-CoV-2. Overall, we suggest that the list of antiviral drugs identified by the MT-DTI model should be considered, when establishing effective treatment strategies for SARS-CoV-2.

show abstract

Section: Discussionsupporting

confidence: 71%

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Beck

Shin

Choi

et al. 2020

Computational and Structural Biotechnology Journal

653

496

View full text Add to dashboard Cite

show abstract

“…17 Cellular & Molecular Immunology Fusion mechanism of 2019-nCoV and fusion inhibitors targeting HR1 domain in spike protein purine nucleoside leading to inaccurate viral RNA synthesis, 36 was originally developed by Toyama Chemical of Japan, and has recently been approved for a clinical trial as a drug to treat COVID-19. 30 Chloroquine, an antimalarial drug, has proven effective in treating coronavirus in China. 32 In addition to the above-mentioned, many other antiviral drugs are also listed.…”

Section: Molecule Antiviral Agents For Covid-19 and Related Coronavirmentioning

confidence: 99%

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

et al. 2020

View full text Add to dashboard Cite

Since the outbreak of the novel coronavirus disease COVID-19, caused by the SARS-CoV-2 virus, this disease has spread rapidly around the globe. Considering the potential threat of a pandemic, scientists and physicians have been racing to understand this new virus and the pathophysiology of this disease to uncover possible treatment regimens and discover effective therapeutic agents and vaccines. To support the current research and development, CAS has produced a special report to provide an overview of published scientific information with an emphasis on patents in the CAS content collection. It highlights antiviral strategies involving small molecules and biologics targeting complex molecular interactions involved in coronavirus infection and replication. The drug-repurposing effort documented herein focuses primarily on agents known to be effective against other RNA viruses including SARS-CoV and MERS-CoV. The patent analysis of coronavirus-related biologics includes therapeutic antibodies, cytokines, and nucleic acid-based therapies targeting virus gene expression as well as various types of vaccines. More than 500 patents disclose methodologies of these four biologics with the potential for treating and preventing coronavirus infections, which may be applicable to COVID-19. The information included in this report provides a strong intellectual groundwork for the ongoing development of therapeutic agents and vaccines.

show abstract

“…FDA-approved drugs provide safe alternatives only in the case where at least modest antiviral activity can be achieved. Accordingly, several drugs are being tested in numerous clinical trials 5 including remdesivir, lopinavir, and chloroquine 6 .…”

Section: Introductionmentioning

confidence: 99%

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Jeon

Lee

et al. 2020

Preprint

View full text Add to dashboard Cite

AbstractCOVID-19 is an emerging infectious disease and was recently declared as a pandemic by WHO. Currently, there is no vaccine or therapeutic available for this disease. Drug repositioning represents the only feasible option to address this global challenge and a panel of 48 FDA-approved drugs that have been pre-selected by an assay of SARS-CoV was screened to identify potential antiviral drug candidates against SARS-CoV-2 infection. We found a total of 24 drugs which exhibited antiviral efficacy (0.1 μM < IC50 < 10 μM) against SARS-CoV-2. In particular, two FDA-approved drugs - niclosamide and ciclesonide – were notable in some respects. These drugs will be tested in an appropriate animal model for their antiviral activities. In near future, these already FDA-approved drugs could be further developed following clinical trials in order to provide additional therapeutic options for patients with COVID-19.

show abstract

More than 80 clinical trials launch to test coronavirus treatments

Cited by 126 publications

References 6 publications

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Predicting commercially available antiviral drugs that may act on the novel coronavirus (SARS-CoV-2) through a drug-target interaction deep learning model

Research and Development on Therapeutic Agents and Vaccines for COVID-19 and Related Human Coronavirus Diseases

Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs

Contact Info

Product

Resources

About